ABBV-2B04 / AbbVie - LARVOL DELTA

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19) (clinicaltrials.gov) - P1; N=25; Completed; Sponsor: AbbVie; Active, not recruiting ➔ Completed

Adverse events • Clinical • Combination therapy • Monotherapy • Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR

Dual-antibody drugs effective against COVID-19 variants in animal study (Reuters) - "COVID-19 therapies made from a cocktail of two types of antibodies were effective against a wide range of variants of the coronavirus in a mice and hamster study...The latest study included three of the four variants that have been designated 'variants of concern' by the World Health Organization...The study, which was conducted in mice and hamsters, tested all single and combination antibody therapies authorized for emergency use by the FDA against emerging international and U.S. variants of the virus....'Resistance arose with some of the monotherapies, but never with combination therapy,' study co-author Jacco Boon wrote."

Preclinical • Infectious Disease • Novel Coronavirus Disease

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. (PubMed, Nature) - "Exceptions were mAb LY-CoV555 and LY-CoV555/LY-CoV016 mono- and combination therapy, which lost all protective activity, and AbbVie 2B04/47D11, which showed partial loss of activity. When administered after infection as therapy, higher doses of several mAb cocktails protected in vivo against viruses with a B.1.351 spike gene. Thus, many, but not all, of the antibody products with Emergency Use Authorization (EUA) should retain substantial efficacy against the prevailing SARS-CoV-2 variant strains."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19) (clinicaltrials.gov) - P1; N=24; Active, not recruiting; Sponsor: AbbVie; Recruiting ➔ Active, not recruiting; N=54 ➔ 24

Adverse events • Clinical • Combination therapy • Enrollment change • Enrollment closed • Monotherapy • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PCR